Clinical Trials at Englewood Hospital: Oncology
EHMC IRB Study #: E-07-304
Dr. Michael Schleider
National Cancer Institute - ECOG
E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB - IIIA Non-Small Cell Lung Cancer
Patients who are at least 18 years old with completely resected Stage IB - IIIA Non-Small Cell Lung Cancer who have not received any prior therapy.
To evaluate the overall survival with chemotherapy with or without bevacizumab used in the adjuvant setting in patients with resected stage IB - IIIA non-small cell lung cancer
Summary of procedures:
The physician will select one of four protocol-approved standard chemotherapy regimens. Then, the patient will be randomized to either Arm A (no bevacizumab ) or Arm B (bevacizumab in addition to the assigned chemotherapy.) All regimens will be given in 3-week cycles for a total of 4 cycles. All patients will be followed for response until progression and for survival for 10 years.
*Each listing only contains a summary of the study information. Please contact the Principal Investigator or Study Coordinator for the full details on a particular study.